Fact checkPoliticsPublished May 18, 2026
Media reports: “The government's plan lets the health secretary override NICE's independent judgement on NHS drug pricing.”. Our verdict: Mostly True.

The claim

“The government's plan lets the health secretary override NICE's independent judgement on NHS drug pricing.”

Media reportsNews reportMay 18, 2026Read the original

Coverage of new regulations on NICE's cost-effectiveness threshold.

Our verdict

Mostly True

New regulations let ministers direct NICE's core cost-effectiveness threshold; campaigners call this an override, the government says the power is limited.

What we found

The government's March 2026 response confirmed a limited ministerial power to set the threshold, raised to £25,000-£35,000 per QALY under the US-UK pharma deal. Campaigners are threatening judicial review. 'Override' is a fair but contested description.

The evidence

1 of 2 sources support the claim; none contradict it.

Contradict 0Support 1Background 1
  • Supports the claim

    The government confirmed a limited power of direction to set NICE's core threshold. [1]

  • Background

    The UK-US pharma deal faces threat of legal challenge. [2]

How we checked

We checked the claim against GOV.UK, The Pharmacist. We reviewed 2 relevant sources.

Sources

  1. [1]GOV.UK · Changes to NICE regulations: cost-effectiveness threshold, government response
  2. [2]The Pharmacist · UK-US pharma deal faces threat of legal challenge

Have evidence we missed?

If you know of a source that confirms or contradicts this claim, send us the link. We review every submission and update fact checks when new evidence changes the picture.

Measured Take updates fact checks when new evidence emerges. Corrections are noted on the page.

All fact checks